Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program

Fig. 5

Kaplan-Meier curves for progression-free survival depending on VEGF-D baseline and objective response dichotomized at the median >712 pg/l. Patients without objective response: Hazard ratio for VEGF-D: 1.192, 95 % CI 0.657–2.164, P = 0.56, N = 46. Patients with objective response: Hazard ratio for VEGF-D: 0.189, 95 % CI 0.056–0.637, P = 0.007, N = 18

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us